Mitotax Paclitaxel 300 mg

Strengths available :  300 mg

Form : Injection

Dosage : Usual Adult Dose for Ovarian Cancer: For previously untreated patients with cancer of the ovary:

175 mg/m2 intravenously over 3 hours every 3 weeks followed by cisplatin or

135 mg/m2 intravenously over 24 hours every 3 weeks followed by cisplatin

For patients previously treated for cancer of the ovary:

175 mg/m2 intravenously over 3 hours every 3 weeks or

135 mg/m2 intravenously over 3 hours every 3 weeks

Usual Adult Dose for Kaposi's Sarcoma:For patients with AIDS-Related Kaposi's Sarcoma:

135 mg/m2 intravenously over 3 hours every 3 weeks or

100 mg/m2 intravenously over 3 hours every 2 weeks

Note: In patients with advanced HIV disease:

1) reduce the dose of dexamethasone as one of the three premedication drugs to 10 mg

2) Initiate or repeat treatment with Mitotax only if the neutrophil count is at least 1000 cells/mm3

3) Reduce the dose of subsequent courses of Mitotax by 20% for patients who experience severe neutropenia (a neutrophi count <500 cells/mm3 for a week or longer)

4) Initiate concomitant hematopoietic growth factor (G-CSF) as clinically indicated.

Usual Adult Dose for Breast Cancer  Adjuvant:For adjuvant treatment of node-positive:

175 mg/m2 intravenously over 3 hours every 3 weeks for four courses administered sequentially to doxorubicin-containing chemotherapy.

Usual Adult Dose for Breast Cancer: After failure of initial chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy:

175 mg/m2 intravenously over 3 hours every 3 weeks

Usual Adult Dose for Non-Small Cell Lung Cancer: 135 mg/m2 intravenously over 24 hours followed by cisplatin every 3 weeks

Storage : Store at room temperature

Common side effects are Swelling and redness at the injection site, Diarrhea, Hair loss or thinning of the hair, Nausea and Vomiting and Joint pain

Pack of 1 vial